A recently conducted review has determined that there’s no correlation between the use of mobile phones and a heightened risk of acoustic neuromas, meningiomas and gliomas. The review also found no correlation between mobile phone use and leukemia or salivary and pituitary cancers.
Mobile phones are low-powered transmitters of radiofrequency-electromagnetic fields. They work by transmitting radio waves to their destinations via cell towers.
The review included 63 studies conducted between 1994 and 2022 and published in more than 20 countries. Each study examined how exposure to radio frequency-electromagnetic fields transmitted by electronic devices, primarily mobile phones, affected the health of individuals.
From the review, the World Health Organization (WHO) notes that these electromagnetic waves are benign, which means they are unable to cause ionization in the body or even damage DNA.
The review found no proof that exposure from fixed-site, radio-frequency-electromagnetic field transmitters such as cell phone towers or broadcasting antennas was associated with pediatric brain tumors or childhood leukemia. This helps reduce any concerns parents may have had. Additionally, fixed workplace radio-frequency-electromagnetic field transmitters weren’t linked to a rise in the incidence of gliomas.
This does not align with a statement made by the International Agency for Research (IARC) on cancer, which rated phones as potentially carcinogenic. To help with this, additional research that aligns with this rating by the IARC has been requested to help rule out any possibility of it being true.
The review’s findings do align with an article published by the IARC that described findings from the COSMOS project. The project investigated the possible long-term health effects of wireless communication technologies, finding that individuals who spent a lot of time on phone calls didn’t have a heightened risk of developing brain tumors in comparison to light users of phones.
Dr. Wael Harb, a board-certified medical oncologist and hematologist who wasn’t part of the WHO review, stated that while older studies had suggested a potential risk, their methodology issues had been criticized. He added that higher quality analysis conducted recently didn’t support the earlier findings, basically debunking claims about increased cancer risks.
With regard to exposure in one’s workplace, Harb explained that while exposure levels at workplaces could sometimes be higher, studies in this field hadn’t shown considerably different impacts on health. Additionally, research hadn’t determined a heightened risk of brain cancer. Regardless, he noted, there was a need for further research to be conducted while individuals minimized their exposure.
The review published its findings in “Environment International.”
As the cases of various brain cancers rise around the world, there is an increasing need to unearth the factors behind this surge and also come up with more effective treatments for the disease. Enterprises such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are investing in searching for better therapeutics against brain cancer, and patients hope the alternatives available to them increase soon.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
